Cue fresh buyout talk: Amarin puts off sales-force decision

Amarin ($AMRN) once again pushed back its marketing timeline for the newly approved heart drug Vascepa. Rather than deciding whether to hire its own sales force as scheduled, it's putting off the decision till mid-December, when it has another chance to score new chemical entity (NCE) status from the FDA. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.